Keppra (Levetiracetam)

Levetiracetam works by binding selectively to the synaptic vesicle protein SV2A, which plays a key role in regulating neurotransmitter release. This binding modulates vesicle exocytosis, decreasing the release of excitatory neurotransmitters and stabilising neuronal membranes, thereby lowering the neuronal hyperexcitability that triggers seizures.

The appropriate dose of Keppra is determined individually by a qualified prescriber based on the patient’s age, weight, renal function, and specific seizure type. Healthcare professionals tailor the dosing regimen to achieve optimal seizure control while minimizing potential side effects.

Levetiracetam is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus, but there are limited human data. It may be used during pregnancy only if the potential benefit justifies any potential risk. Limited data suggest it is excreted in breast milk; breastfeeding decisions should be made in consultation with a healthcare provider.

To order Keppra, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide your institutional or trade credentials. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, then replies with pricing, availability, shipping details (including cold‑chain handling if required), and the necessary import documentation.

Compared with older agents such as carbamazepine or valproate, levetiracetam has a distinct mechanism (SV2A binding) and a relatively favourable drug‑interaction profile. It does not induce hepatic enzymes, reducing the likelihood of altering the levels of concomitant medications. However, individual response varies, and clinicians consider seizure type, tolerability, and comorbidities when selecting therapy.

Keppra injectable solution should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the product. If the solution reaches room temperature, it may be used within the time frame specified in the product labeling.

Keppra is supplied as an injectable solution for intravenous administration. It can be given as a slow IV infusion or bolus injection, according to the prescribing information. The route ensures rapid systemic exposure, which is useful for patients who cannot take oral medications or require immediate seizure control.

Serious adverse reactions, although uncommon, include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and significant psychiatric effects like new‑onset depression, suicidal ideation, or severe mood changes. Rare hematologic abnormalities and respiratory depression have also been reported. Prompt medical evaluation is essential if any of these events occur.

Keppra is contraindicated in individuals with a known hypersensitivity to levetiracetam or any component of the formulation. Caution is advised for patients with severe renal impairment, as dose adjustments may be required. Pregnant or breastfeeding women should only use it when clearly indicated by a healthcare professional, weighing potential benefits against risks.